A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., Maryland 20016, United States
Towong, Queensland 4066, Australia